Sunesis Pharmaceuticals (SNSS) Misses Q4 EPS by 1c

March 9, 2017 7:05 AM EST

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $600 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings